Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics (MLTX), sold 200,000 shares at $59.22 ($11.8M) on 2023-12-19, disclosed to the SEC on 2023-12-21.
Scheduled sale ($11.8M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $59.22 | 94,736 | $5.6M | 47.4% |
| 2 | $59.22 | 94,736 | $5.6M | 47.4% |
| 3 | $58.34 | 5,264 | $307K | 2.6% |
| 4 | $58.34 | 5,264 | $307K | 2.6% |
| Total | $59.17 avg | 200,000 | $11.8M | 100% |
| Filing → |
| MLTX | SELL | 2026-05-13 | $273K | — | Filing → |
| MLTX | SELL | 2026-04-16 | $47K | — | Filing → |
| MLTX | SELL | 2026-04-10 | $1.7M | — | Filing → |